J. Goldman & Co’s Abivax ABVX Stock Holding History

J. Goldman & Co’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.27M	Buy	+9,500	New	+$1.08M	0.03%	415

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

J. Goldman & Co's ABVX Position: Q2 2026 in Review

J. Goldman & Co reduced its Abivax (ABVX) stake by 57% in Q2 2026, selling an estimated $827K and leaving 5,446 shares worth $726K. The position accounts for 0.02% of the portfolio, ranked #501.

J. Goldman & Co first reported a position in ABVX in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.41M in Q3 2025. 304 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

J. Goldman & Co held 5,446 shares of Abivax worth $726K as of Q2 2026.
J. Goldman & Co sold 7,303 Abivax shares in Q2 2026, an estimated $827K.
Abivax made up 0.02% of J. Goldman & Co's portfolio in Q2 2026, its #501 holding.
J. Goldman & Co first reported a position in Abivax in Q2 2025 and has held it in 5 quarters since.
J. Goldman & Co's Abivax position peaked at $4.41M in Q3 2025.
304 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.